22-23960298-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4BS2_Supporting
The NM_001080843.4(GSTT2B):c.196G>A(p.Glu66Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0019 in 1,612,624 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0015 ( 0 hom., cov: 30)
Exomes 𝑓: 0.0019 ( 2 hom. )
Consequence
GSTT2B
NM_001080843.4 missense
NM_001080843.4 missense
Scores
2
10
7
Clinical Significance
Conservation
PhyloP100: 4.04
Genes affected
GSTT2B (HGNC:33437): (glutathione S-transferase theta 2B) The protein encoded by this gene, glutathione S-transferase (GST) theta 2B (GSTT2B), is a member of a superfamily of proteins that catalyze the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds. Human GSTs can be divided into five main classes: alpha, mu, pi, theta, and zeta. The theta class includes GSTT1, GSTT2, and GSTT2B. GSTT2 and GSTT2B are nearly identical to each other, and share 55% amino acid identity with GSTT1. All three genes may play a role in human carcinogenesis. The GSTT2B gene is a pseudogene in some populations. [provided by RefSeq, Sep 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.3751099).
BS2
High Homozygotes in GnomAdExome4 at 2 AR geneVariant has number of homozygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GSTT2B | NM_001080843.4 | c.196G>A | p.Glu66Lys | missense_variant | 2/5 | ENST00000290765.9 | |
GSTT2B | NM_001363804.1 | c.196G>A | p.Glu66Lys | missense_variant | 2/5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GSTT2B | ENST00000290765.9 | c.196G>A | p.Glu66Lys | missense_variant | 2/5 | 1 | NM_001080843.4 | P1 | |
GSTT2B | ENST00000404172.3 | c.196G>A | p.Glu66Lys | missense_variant | 2/5 | 1 |
Frequencies
GnomAD3 genomes AF: 0.00155 AC: 235AN: 151756Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
235
AN:
151756
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00196 AC: 78AN: 39848Hom.: 0 AF XY: 0.00204 AC XY: 41AN XY: 20128
GnomAD3 exomes
AF:
AC:
78
AN:
39848
Hom.:
AF XY:
AC XY:
41
AN XY:
20128
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00193 AC: 2824AN: 1460750Hom.: 2 Cov.: 32 AF XY: 0.00196 AC XY: 1427AN XY: 726706
GnomAD4 exome
AF:
AC:
2824
AN:
1460750
Hom.:
Cov.:
32
AF XY:
AC XY:
1427
AN XY:
726706
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00154 AC: 234AN: 151874Hom.: 0 Cov.: 30 AF XY: 0.00132 AC XY: 98AN XY: 74222
GnomAD4 genome
AF:
AC:
234
AN:
151874
Hom.:
Cov.:
30
AF XY:
AC XY:
98
AN XY:
74222
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ExAC
AF:
AC:
3
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 26, 2021 | The c.196G>A (p.E66K) alteration is located in exon 2 (coding exon 2) of the GSTT2B gene. This alteration results from a G to A substitution at nucleotide position 196, causing the glutamic acid (E) at amino acid position 66 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Uncertain
D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
H;.
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D
REVEL
Uncertain
Sift
Uncertain
D;D
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MutPred
Gain of methylation at E66 (P = 0.01);Gain of methylation at E66 (P = 0.01);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at